The global glaucoma surgery devices market size to be valued at USD 2.6 billion by 2027 and is expected to grow at a compound annual growth rate (CAGR) of 6.9% during the forecast period. The rising global burden of glaucoma is expected to contribute to market growth over the forecast period. As per the data published in 2014 by the American Academy of Ophthalmology (AAO), the global prevalence of glaucoma was estimated to be 64.3 million in 2013 and is expected to reach 76 million by 2020 and further to 111.8 million by 2040.
Therefore, expansion of the patient base, coupled with improvement in the healthcare facilities, is expected to increase the demand for surgery devices, thereby aiding the market growth. In addition, government support such as favorable reimbursement policies and foreign direct investment provisions is expected to drive the market for these surgery devices, especially in developing regions.
Rising demand for minimal invasive glaucoma surgery (MIGS) procedures is expected to drive the demand for advanced glaucoma surgery devices over the forecast period. Benefits, such as reduced surgery time, shorter recovery period, affordability, and low risk of post-surgical complications, including hypotony, are increasing the demand for MIGS procedures and devices.
In recent years, patients have been opting for permanent surgical solutions over long term management with prescription drugs. Glaucoma patients are usually characterized by taking 2 or more different medications depending upon the stage of glaucoma, thus creating a lot of patient compliance issues. Undergoing a glaucoma surgery significantly reduces the medication burden of the patients. Additionally, therapeutic efficiency problems associated with medication, such as low bioavailability, drug resistance, and toxicity, have increased the demand for surgical procedures and devices, thereby fostering the market growth.
Surge in the number of glaucoma care initiatives conducted by the government and several non-governmental organizations is expected to have a positive impact on the adoption of advanced devices. These organizations conduct eye check-up and mass surgery camps, spread awareness, and provide funding for surgical procedures and devices. Such initiatives have reduced the percentage of undiagnosed cases of glaucoma, concomitantly fueling the demand for glaucoma treatment procedures and devices.
The presence of a large geriatric population globally and a more susceptible population to vision impairment is driving the global market. Furthermore, increasing demand for minimally invasive glaucoma surgery (MIGS) treatments and technological improvements in surgery equipment is expected to propel the market growth.
Factors such as reimbursement obstacles for MIGS devices and increasing concerns regarding post-operative problems associated with glaucoma procedures are anticipated to limit the market growth in the coming years. Furthermore, the market is also affected by a shortage of qualified experts to perform glaucoma surgeries and a lack of awareness about eye care, specifically in emerging economies.
As healthcare costs rise, reimbursement decreases, and the need to find new ways of excellent medical treatment expands. This provides business opportunities to cater to the market demand and improve business products and operations.
Based on product, the market is classified into punches, USC marker, USC planner, USC shaver, forceps, algerbrush, probes, diamond knives, glaucoma drainage device (shunts, stents, implants, valve), laser system, and others (cannula, speculum, needle holders, scissors).
Glaucoma drainage devices held the largest market share in 2019 and are expected to expand at the fastest CAGR over the forecast period. Cataract surgery and glaucoma surgeries are often performed in combination. High procedural volume of cataract surgeries is expected to have a direct positive impact on the segment growth. The MIGS drainage device, called iStent, has recently been approved by the U.S. FDA for use in combination with cataract surgery. Furthermore, the advent of novel and advanced MIGS devices, such as Microhook ab interno LOT (µLOT) and Trabectome, is expected to boost the growth of the glaucoma drainage devices segment over the forecast period.
Products such as forceps, algerbrush, probes, scissors, needle holders, and diamond knives individually held a decent share in the market in 2019 and are expected to witness steady growth over the forecast period. The segment space is highly fragmented with the presence of a large number of market players. Most of the users prefer buying from local market players, which offer products and devices at a relatively lower price. Increasing demand for surgical devices in underdeveloped countries of MENA is expected to boost the growth of these segments over the forecast period.
Based on the surgery method, the global glaucoma surgery devices market is segmented into traditional glaucoma surgery, minimally invasive glaucoma surgery, and laser surgery. The traditional glaucoma surgery segment is further divided into trabeculectomy and tube shunt surgery. Minimal invasive glaucoma surgery (MIGS) is further segmented into trabecular meshwork bypass, suprachoroidal space implants, and subconjunctival space implants. Laser surgery is sub-segmented into trabeculoplasty, iridotomy, and cyclophotocoagulation.
The traditional glaucoma surgery segment held the largest market share in 2019. Longer hospital stays, availability of other advanced surgical technology and devices, and increased chances of postoperative complications, such as leakage, hypotony, choroidal effusion, and hyphema, are some of the factors driving the patients and surgeons to opt for alternatives. However, traditional surgery is still the first choice in developing countries, where the healthcare service industry is dominated by private players. As per the NCBI report, a subconjunctival space implant is approximately 3.5 times costlier than trabeculectomy. Therefore, this surgery method has great potential for growth, especially in underdeveloped economies such as North African countries.
MIGS held a significant proportion in the market for glaucoma surgery device in 2019 and is expected to expand at a healthy CAGR over the forecast period. Clinical evidences suggesting the use of two iStent’s (MIGS devices) for an efficient treatment of glaucoma are expected to drive the segment. Furthermore, frequent launches of advanced glaucoma drainage devices are expected to boost the segment growth over the forecast period. For instance, Ivantis, a company dedicated to the development of new solutions and devices for glaucoma treatment, received approval from the U.S. FDA for the launch of its MIGS device called “Hydrus Microstent” in 2018.
Based on end user, the market is segmented into hospitals, ophthalmic clinics, and others. The hospital segment held the largest share in the market in 2019 and is expected to exhibit a lucrative CAGR over the forecast period. Large patient base, availability of highly skilled medical professionals, and advanced surgical devices are the key factors expected to boost the segment growth.
Ophthalmic clinics held the second largest share in 2019 and are expected to witness the fastest growth over the forecast period. Introduction of advanced surgical devices, cost efficiency, shorter waiting time, and rising awareness about MIGS surgery and treatment devices are expected to boost the segment growth during the forecast period.
The others segment includes academics, research institutes, and mobile ophthalmic units. The segment is expected to expand at a healthy CAGR over the forecast. Rising number of undiagnosed glaucoma cases, increasing investments in glaucoma research, and poor healthcare facilities in remote areas are a few of the factors expected to fuel the segment growth over the forecast period.
North America held the largest market share in 2019. Presence of leading market players, efficient reimbursement policies, and public health programs, such as Eye America and Vision USA, are the factors expected to drive the regional market over the forecast period. As per the Glaucoma Research Foundation report of 2018, over 3 million Americans are living with glaucoma and this number is expected to double by 2050. Additionally, increasing awareness about glaucoma and early product availability are the factors expected to aid the market growth.
Europe held the second-largest share in 2019. The region has a dynamic reimbursement paradigm for glaucoma surgery, where some countries are having proper coverage on modern surgery devices and methods while others must cater to trabeculectomy despite the availability of wider options. European countries such as Germany, France, and Russia have the highest number of glaucoma surgeries performed annually in the world.
Asia Pacific is expected to witness the fastest growth over the forecast period. Large unmet needs, coupled with increasing incidence of open-angle glaucoma, especially in countries such as Japan, China, and India, are expected to fuel the growth of the market in this region. Additionally, the region is expected to witness high demand for MIGS devices due to its continuous improvement in the healthcare facilities and resources.
The market is highly fragmented and leading players present in the market are Alcon, Inc.; Glaukos Corporation; Abbott Medical Optics; Allergan Plc.; ASICO; Carl Zeiss Meditec AG; Katalyst Surgical; Lumenis Ltd.; Ziemer Ophthalmic Systems AG; and Iridex Corporation. Key players in the market for glaucoma surgery devices are adopting strategic initiatives, such as mergers and acquisitions, to strengthen their product portfolio in the glaucoma treatment devices segment.
For instance, in August 2019, Glaukos, an ophthalmic medical technology, and pharmaceutical company, entered into a definitive agreement to acquire Avedro, a leading hybrid ophthalmic medical technology company. The acquisition helped Glaukos to expand its product portfolio in glaucoma treatment and enhance its R&D, clinical, and regulatory capabilities.
In November 2021, The Hydrus Microstent for Surgical Glaucoma was acquired by Alcon from Ivantis, Inc. The planned acquisition underlined Alcon's adherence to the market, adding to the company's already industry-leading range of cataract, retina, refractive, and glaucoma treatments
In May 2020, Allergan plc was acquired by AbbVie Inc, a pharmaceutical, biological, surgical, and regenerative medicine company focused on developing, manufacturing, and commercializing branded medicine products across the globe
In April 2020, Carl Zeiss Meditec acquired two surgical instrument manufacturers, Kogent Surgical and Katalyst Surgical. This acquisition was aimed at scaling the businesses and contributing to providing surgical solution offerings
Revenue forecast in 2027
USD 2.6 billion
CAGR of 6.9% from 2020 to 2027
Base year for estimation
2016 - 2018
2020 - 2027
Revenue in USD billion and CAGR from 2020 to 2027
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Product, surgery method, end user, and region
North America; Europe; Asia Pacific; Latin America; Middle East & Africa
U.S.; Canada; U.K.; Germany; France; Italy; Spain; Switzerland; The Netherlands; Russia; Sweden; Belgium; China; India; Japan; Thailand; South Korea; Indonesia; Philippines; Vietnam; Malaysia; Singapore; Mexico; Brazil; Colombia; Argentina; Chile; South Africa; Saudi Arabia; UAE; Kuwait; Israel
Key companies profiled
Alcon, Inc.; Glaukos Corporation; Abbott Medical Optics; Allergan Plc.; ASICO; Carl Zeiss Meditec AG; Katalyst Surgical; Lumenis Ltd.; Ziemer Ophthalmic Systems AG; Iridex Corporation.
Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country; regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the global glaucoma surgery devices market report on the basis of product, surgery method, end user, and region:
Product Outlook (Revenue, USD Million, 2016 - 2027)
Glaucoma Drainage Device (Shunts, Stents, Implants, Valve)
Others (Cannula, Speculum, Needle Holders, Scissors)
Surgery Method Outlook (Revenue, USD Million, 2016 - 2027)
Traditional Glaucoma Surgery
Tube Shunt Surgery
Minimal Invasive Glaucoma Surgery
Trabecular Meshwork Bypass
Suprachoroidal Space Implants
Subconjunctival Space Implants
End-user Outlook (Revenue, USD Million, 2016 - 2027)
Regional Outlook (Revenue, USD Million, 2016 - 2027)
Middle East & Africa
b. The global glaucoma surgery devices market size was estimated at USD 1.5 billion in 2019 and is expected to reach USD 1.6 billion in 2020.
b. The global glaucoma surgery devices market is expected to grow at a compound annual growth rate of 6.92% from 2020 to 2027 to reach USD 2.6 billion by 2027.
b. North America dominated the glaucoma surgery devices market with a share of 35.72% in 2019. This is attributable to the presence of leading market players, efficient reimbursement policies, and public health programs related to eyecare(Eye America, Vision USA).
b. Some key players operating in the glaucoma surgery devices market include Alcon, Inc.; Glaukos Corporation; Abbott Medical Optics; Allergan Plc.; ASICO; Carl Zeiss Meditec AG; Katalyst Surgical; Lumenis Ltd.; Ziemer Ophthalmic Systems AG; and Iridex Corporation.
b. Key factors that are driving the market growth include the rising prevalence of glaucoma, growing demand for minimally invasive glaucoma procedures, and increasing participation of public and private sectors in sponsoring glaucoma surgery.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.